Natural Product Hybrids as New Leads for Drug Discovery

Natural products play an important role in the development of drugs, especially for the treatment of infections and cancer, as well as immunosuppressive compounds. However, the number of natural products is limited, whereas millions of hybrids as combinations of parts of different natural products c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Angewandte Chemie International Edition 2003-09, Vol.42 (34), p.3996-4028
Hauptverfasser: Tietze, Lutz F., Bell, Hubertus P., Chandrasekhar, Srivari
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4028
container_issue 34
container_start_page 3996
container_title Angewandte Chemie International Edition
container_volume 42
creator Tietze, Lutz F.
Bell, Hubertus P.
Chandrasekhar, Srivari
description Natural products play an important role in the development of drugs, especially for the treatment of infections and cancer, as well as immunosuppressive compounds. However, the number of natural products is limited, whereas millions of hybrids as combinations of parts of different natural products can be prepared. This new approach seems to be very promising in the development of leads for both medicinal and agrochemical applications, as the biological activity of several new hybrids exceeds that of the parent compounds. The advantage of this concept over a combinatorial chemistry approach is the high diversity and the inherent biological activity of the hybrids. Unlimited options: The synthesis of natural product hybrids by combining structurally different, naturally occurring compounds that exhibit high biological activities appears to be a promising approach to increase the number and diversity of substances for pharmacological testing. An example is the hybrid of estrone and (−)‐talaromycin (see picture).
doi_str_mv 10.1002/anie.200200553
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73661287</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73661287</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4853-c2f902933ccd5a5fb34de9ba4b45915ab89884bb2cce1dbfb04dfdb17d9639353</originalsourceid><addsrcrecordid>eNqFkElPwzAQRi0EolC4ckQ5cUvxEsfxsRtdiApCII6Wt6BA2hQ7ofTfkypV4cZpZqT3PY0-AK4Q7CEI8a1c5baHmw1CSskROEMUo5AwRo6bPSIkZAlFHXDu_XtDJQmMT0EHYc4Io_wMsIWsaieL4NGVptZVMN0qlxsfSB8s7CZIrWyOrHTByNVvwSj3uvyybnsBTjJZeHu5n13wcjd-Hk7D9GEyG_bTUEcJJaHGGYeYE6K1oZJmikTGciUjFVGOqFQJT5JIKay1RUZlCkYmMwoxw2PCCSVdcNN61678rK2vxLJ5wRaFXNmy9oKROEY4YQ3Ya0HtSu-dzcTa5UvptgJBsatK7KoSh6qawPXeXKulNb_4vpsG4C2wyQu7_Ucn-ovZ-K88bLO5r-z3ISvdh4h3dvG6mAj8NJjfp4O5oOQHpEWD4w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73661287</pqid></control><display><type>article</type><title>Natural Product Hybrids as New Leads for Drug Discovery</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Tietze, Lutz F. ; Bell, Hubertus P. ; Chandrasekhar, Srivari</creator><creatorcontrib>Tietze, Lutz F. ; Bell, Hubertus P. ; Chandrasekhar, Srivari</creatorcontrib><description>Natural products play an important role in the development of drugs, especially for the treatment of infections and cancer, as well as immunosuppressive compounds. However, the number of natural products is limited, whereas millions of hybrids as combinations of parts of different natural products can be prepared. This new approach seems to be very promising in the development of leads for both medicinal and agrochemical applications, as the biological activity of several new hybrids exceeds that of the parent compounds. The advantage of this concept over a combinatorial chemistry approach is the high diversity and the inherent biological activity of the hybrids. Unlimited options: The synthesis of natural product hybrids by combining structurally different, naturally occurring compounds that exhibit high biological activities appears to be a promising approach to increase the number and diversity of substances for pharmacological testing. An example is the hybrid of estrone and (−)‐talaromycin (see picture).</description><identifier>ISSN: 1433-7851</identifier><identifier>EISSN: 1521-3773</identifier><identifier>DOI: 10.1002/anie.200200553</identifier><identifier>PMID: 12973759</identifier><language>eng</language><publisher>Weinheim: WILEY-VCH Verlag</publisher><subject>Animals ; biological activity ; Biological Factors - chemistry ; Biological Factors - pharmacology ; combinatorial chemistry ; Drug Design ; Drug Evaluation, Preclinical - methods ; Humans ; hybrids ; Molecular Structure ; natural products ; Pharmaceutical Preparations - chemical synthesis ; Pharmaceutical Preparations - chemistry</subject><ispartof>Angewandte Chemie International Edition, 2003-09, Vol.42 (34), p.3996-4028</ispartof><rights>Copyright © 2003 WILEY‐VCH Verlag GmbH &amp; Co. KGaA, Weinheim</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4853-c2f902933ccd5a5fb34de9ba4b45915ab89884bb2cce1dbfb04dfdb17d9639353</citedby><cites>FETCH-LOGICAL-c4853-c2f902933ccd5a5fb34de9ba4b45915ab89884bb2cce1dbfb04dfdb17d9639353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fanie.200200553$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12973759$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tietze, Lutz F.</creatorcontrib><creatorcontrib>Bell, Hubertus P.</creatorcontrib><creatorcontrib>Chandrasekhar, Srivari</creatorcontrib><title>Natural Product Hybrids as New Leads for Drug Discovery</title><title>Angewandte Chemie International Edition</title><addtitle>Angewandte Chemie International Edition</addtitle><description>Natural products play an important role in the development of drugs, especially for the treatment of infections and cancer, as well as immunosuppressive compounds. However, the number of natural products is limited, whereas millions of hybrids as combinations of parts of different natural products can be prepared. This new approach seems to be very promising in the development of leads for both medicinal and agrochemical applications, as the biological activity of several new hybrids exceeds that of the parent compounds. The advantage of this concept over a combinatorial chemistry approach is the high diversity and the inherent biological activity of the hybrids. Unlimited options: The synthesis of natural product hybrids by combining structurally different, naturally occurring compounds that exhibit high biological activities appears to be a promising approach to increase the number and diversity of substances for pharmacological testing. An example is the hybrid of estrone and (−)‐talaromycin (see picture).</description><subject>Animals</subject><subject>biological activity</subject><subject>Biological Factors - chemistry</subject><subject>Biological Factors - pharmacology</subject><subject>combinatorial chemistry</subject><subject>Drug Design</subject><subject>Drug Evaluation, Preclinical - methods</subject><subject>Humans</subject><subject>hybrids</subject><subject>Molecular Structure</subject><subject>natural products</subject><subject>Pharmaceutical Preparations - chemical synthesis</subject><subject>Pharmaceutical Preparations - chemistry</subject><issn>1433-7851</issn><issn>1521-3773</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkElPwzAQRi0EolC4ckQ5cUvxEsfxsRtdiApCII6Wt6BA2hQ7ofTfkypV4cZpZqT3PY0-AK4Q7CEI8a1c5baHmw1CSskROEMUo5AwRo6bPSIkZAlFHXDu_XtDJQmMT0EHYc4Io_wMsIWsaieL4NGVptZVMN0qlxsfSB8s7CZIrWyOrHTByNVvwSj3uvyybnsBTjJZeHu5n13wcjd-Hk7D9GEyG_bTUEcJJaHGGYeYE6K1oZJmikTGciUjFVGOqFQJT5JIKay1RUZlCkYmMwoxw2PCCSVdcNN61678rK2vxLJ5wRaFXNmy9oKROEY4YQ3Ya0HtSu-dzcTa5UvptgJBsatK7KoSh6qawPXeXKulNb_4vpsG4C2wyQu7_Ucn-ovZ-K88bLO5r-z3ISvdh4h3dvG6mAj8NJjfp4O5oOQHpEWD4w</recordid><startdate>20030905</startdate><enddate>20030905</enddate><creator>Tietze, Lutz F.</creator><creator>Bell, Hubertus P.</creator><creator>Chandrasekhar, Srivari</creator><general>WILEY-VCH Verlag</general><general>WILEY‐VCH Verlag</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030905</creationdate><title>Natural Product Hybrids as New Leads for Drug Discovery</title><author>Tietze, Lutz F. ; Bell, Hubertus P. ; Chandrasekhar, Srivari</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4853-c2f902933ccd5a5fb34de9ba4b45915ab89884bb2cce1dbfb04dfdb17d9639353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Animals</topic><topic>biological activity</topic><topic>Biological Factors - chemistry</topic><topic>Biological Factors - pharmacology</topic><topic>combinatorial chemistry</topic><topic>Drug Design</topic><topic>Drug Evaluation, Preclinical - methods</topic><topic>Humans</topic><topic>hybrids</topic><topic>Molecular Structure</topic><topic>natural products</topic><topic>Pharmaceutical Preparations - chemical synthesis</topic><topic>Pharmaceutical Preparations - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tietze, Lutz F.</creatorcontrib><creatorcontrib>Bell, Hubertus P.</creatorcontrib><creatorcontrib>Chandrasekhar, Srivari</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Angewandte Chemie International Edition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tietze, Lutz F.</au><au>Bell, Hubertus P.</au><au>Chandrasekhar, Srivari</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Natural Product Hybrids as New Leads for Drug Discovery</atitle><jtitle>Angewandte Chemie International Edition</jtitle><addtitle>Angewandte Chemie International Edition</addtitle><date>2003-09-05</date><risdate>2003</risdate><volume>42</volume><issue>34</issue><spage>3996</spage><epage>4028</epage><pages>3996-4028</pages><issn>1433-7851</issn><eissn>1521-3773</eissn><abstract>Natural products play an important role in the development of drugs, especially for the treatment of infections and cancer, as well as immunosuppressive compounds. However, the number of natural products is limited, whereas millions of hybrids as combinations of parts of different natural products can be prepared. This new approach seems to be very promising in the development of leads for both medicinal and agrochemical applications, as the biological activity of several new hybrids exceeds that of the parent compounds. The advantage of this concept over a combinatorial chemistry approach is the high diversity and the inherent biological activity of the hybrids. Unlimited options: The synthesis of natural product hybrids by combining structurally different, naturally occurring compounds that exhibit high biological activities appears to be a promising approach to increase the number and diversity of substances for pharmacological testing. An example is the hybrid of estrone and (−)‐talaromycin (see picture).</abstract><cop>Weinheim</cop><pub>WILEY-VCH Verlag</pub><pmid>12973759</pmid><doi>10.1002/anie.200200553</doi><tpages>33</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1433-7851
ispartof Angewandte Chemie International Edition, 2003-09, Vol.42 (34), p.3996-4028
issn 1433-7851
1521-3773
language eng
recordid cdi_proquest_miscellaneous_73661287
source MEDLINE; Access via Wiley Online Library
subjects Animals
biological activity
Biological Factors - chemistry
Biological Factors - pharmacology
combinatorial chemistry
Drug Design
Drug Evaluation, Preclinical - methods
Humans
hybrids
Molecular Structure
natural products
Pharmaceutical Preparations - chemical synthesis
Pharmaceutical Preparations - chemistry
title Natural Product Hybrids as New Leads for Drug Discovery
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T20%3A28%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Natural%20Product%20Hybrids%20as%20New%20Leads%20for%20Drug%20Discovery&rft.jtitle=Angewandte%20Chemie%20International%20Edition&rft.au=Tietze,%20Lutz%20F.&rft.date=2003-09-05&rft.volume=42&rft.issue=34&rft.spage=3996&rft.epage=4028&rft.pages=3996-4028&rft.issn=1433-7851&rft.eissn=1521-3773&rft_id=info:doi/10.1002/anie.200200553&rft_dat=%3Cproquest_cross%3E73661287%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73661287&rft_id=info:pmid/12973759&rfr_iscdi=true